Gilead Sciences agreed to acquire drug developer Pharmasset in a deal valued at about $10.4 billion.
Gilead Sciences to buy Pharmasset
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.